Aripiprazole Tablet
Product Images NDC 67877-434

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 67877-434). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ascend Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Aripiprazole-fig-16.jpg (Aripiprazole Fig 16)

A line graph comparing the proportion of subjects with relapse over 182 days from randomization between Aripiprazole and placebo groups. The x-axis shows days from randomization, and the y-axis shows the proportion with relapse. The graph includes numbers of subjects at risk for each group at various time points.*

FDA Label Image

Aripiprazole-fig-17 (Aripiprazole Fig 17)

A line graph comparing the proportion of relapse over days from randomization between Aripiprazole and placebo groups. The graph shows two lines: a solid line for Aripiprazole and a dashed line for placebo, with the placebo group showing a higher proportion of relapse over time. The x-axis represents days from randomization up to 364 days, and the y-axis represents the proportion with relapse from 0 to 1. Below the x-axis is a table indicating the number of subjects at risk in each group at various time points.*

FDA Label Image

Effects Of Other Drugs On Dehydro-aripiprazole (Aripiprazole Fig10)

A pharmacokinetic chart titled 'Dehydro-Aripiprazole Fold Change and 90% CI' showing the relative change in AUC and Cmax values compared to a reference without interacting drug. The chart includes data points for various inhibitors, inducers, gastric acid blockers, and other drugs affecting Aripiprazole metabolism, with error bars indicating 90% confidence intervals.*

FDA Label Image

Effects Of Aripiprazole On Pharmacokinetics Of Other Drugs (Aripiprazole Fig11)

A chart depicting fold changes and 90% confidence intervals for various pharmacokinetic parameters (DMVDRP, AUC, Cmax, INR) of drugs including dextromethorphan, warfarin, omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, and escitalopram, showing changes relative to a reference without interacting drug.*

FDA Label Image

Effects Of Intrinsic Factors On Aripiprazole (Aripiprazole Fig12)

A pharmacokinetic chart titled 'Aripiprazole Fold Change and 90% CI' showing changes in AUC and Cmax related to various factors: CYP2D6 metabolism status, gender, age groups, hepatic impairment severity, and severe renal impairment. The horizontal axis represents change relative to reference values, with data points and confidence intervals for each factor comparison.*

FDA Label Image

Effects Of Intrinsic Factors On Dehydro-aripiprazole (Aripiprazole Fig13)

A pharmacokinetic chart showing fold change and 90% confidence intervals of Dehydro-Aripiprazole relative to reference. The chart compares exposure metrics (AUC and Cmax) for multiple factors including CYP2D6 metabolism status, gender, age groups, hepatic impairment severity, and severe renal impairment.*

FDA Label Image

Effects Of Other Drugs On Aripiprazole (Aripiprazole Fig9)

A scatter plot showing the fold change and 90% confidence intervals of Aripiprazole pharmacokinetic parameters AUC and Cmax relative to reference without interacting drugs. The chart compares effects of various inhibitors and inducers including CYP3A4 inhibitor ketoconazole, CYP2D6 inhibitor quinidine, CYP3A4 inducer carbamazepine, gastric acid blocker famotidine, and other drugs such as valproate, lithium, and lorazepam.*

FDA Label Image

Aripiprazole Fig1

Label for Aripiprazole Tablets, USP 2 mg oral tablets, manufactured by Alkem Laboratories Ltd. and distributed by Ascend Laboratories, LLC. The label specifies storage conditions, dosage guidance to refer to package insert, and contains a note to dispense the enclosed medication guide. The package contains 30 tablets.*

FDA Label Image

Aripiprazole Fig2

Label for Aripiprazole Tablets USP 5 mg, manufactured by Alkem Laboratories Ltd. and distributed by Ascend Laboratories, LLC. The label indicates 100 tablets in the package, with storage instructions and a barcode. It includes a note to dispense the enclosed medication guide to each patient and specifies Rx only.*

FDA Label Image

Aripiprazole Fig3

Label for Aripiprazole Tablets USP 10 mg by Ascend Laboratories, LLC. The label includes storage instructions, dosage guidance reference, and a note to keep medicines out of children's reach. It states the tablets are manufactured by Alkem Laboratories Ltd., India, and distributed by Ascend Laboratories, LLC, Parsippany, NJ. The quantity is 500 tablets, with a barcode and NDC 67877-432-05 visible.*

FDA Label Image

Aripiprazole Fig4

Label for Aripiprazole Tablets USP 15 mg oral tablets, packaged 30 tablets per container. The label includes storage instructions, manufacturer information (Alkem Laboratories Ltd., India), and distributor details (Ascend Laboratories, LLC). It features a barcode and a note to dispense the enclosed medication guide to each patient.*

FDA Label Image

Aripiprazole Fig5

Label for Aripiprazole Tablets USP 20 mg by Ascend Laboratories, LLC. The label indicates the product contains 20 mg Aripiprazole per tablet, with a quantity of 100 tablets. It includes storage instructions, manufacturer Alkem Laboratories Ltd., India, and distributor Ascend Laboratories, Parsippany, NJ. The label also features barcodes and a note to dispense the enclosed Medication Guide.*

FDA Label Image

Aripiprazole Fig6

The label for Aripiprazole Tablets, USP 30 mg shows branding by Ascend Laboratories, LLC. It states each tablet contains 30 mg of Aripiprazole and provides storage instructions. The label indicates a package of 500 tablets, Rx only, manufactured by Alkem Laboratories Ltd., India, and distributed by Ascend Laboratories, Parsippany, NJ. A barcode and NDC number 67877-435-05 are visible.*

FDA Label Image

Aripiprazole Structure (Aripiprazole Fig8)

Chemical structure of aripiprazole showing its molecular arrangement including chlorinated phenyl, piperazine ring, and quinolinone components.*

FDA Label Image

Aripiprazole-graph (Aripiprazole Graph)

A line graph comparing the proportion of subjects with relapse over 182 days from randomization between Aripiprazole and placebo groups. The x-axis shows days from randomization, and the y-axis shows the proportion with relapse. The graph includes numbers of subjects at risk over time for both groups, with the Aripiprazole group represented by a blue solid line and the placebo group by a red dashed line.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.